(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Monday said it continued its "strong progress" in the first half of 2026. Read More
Avacta Group PLC - London-based clinical-stage biopharmaceutical company - Raises gross proceeds of approximately GBP9 million from institutional investors and existing shareholders, through conditionally placing 12.8 million new shares at 70 pence each. Says one institutional cornerstone investor represents the majority of the funds. Notes that as of late August, the terms of its convertible bond were renegotiated to defer quarterly repayments and interest until October 20, 2027. The bondholder can accelerate the satisfaction of the quarterly repayments from October 1 this year. It will also have the right to accelerate satisfaction of one or both deferred repayments upon publication of Avacta's data readouts from its phase 1b trials of AVA6000 in triple-negative breast cancer or, if earlier, June 30. Avacta says the net placing proceeds will enable it to make the deferred repayments in cash, and make an additional quarterly payment in cash if required. Also notes that Chief Executive Officer Christina Coughlin and Non-Executive Director Mark Goldberg have both invested approximately GBP22,500 by subscribing for 32,142 shares each at the issue price. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Tuesday said clinical data from two cancer trials is expected to be released this year as it reported a widened annual pretax loss. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued last Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Thursday said it "continued to build momentum" in the first quarter, highlighting favourable developments for its oncology products. Read More
Avacta Group PLC - London-based biopharmaceutical company developing a tumour-activated oncology delivery platform - Raises GBP10 million from a placing of and subscription to 15.9 million new shares at 63 pence each. The new shares represent 3.6% of Avacta's total prior to the issuance. Two non-executive directors, Richard Hughes and David Bryant, contribute a total of GBP550,000 to the raise. The share offer is run by Zeus Capital as broker and bookrunner. Zeus will receive warrants over 4.4 million new shares at the same 63p price, exercisable over five years. The raise is in line with the plan announced after the London market close on Thursday. The fresh cash will be used to progress Avacta's research and development programmes into early in the first quarter of 2027, providing enough cash to get to initial data from a phase 1a trial of AVA6103, its second clinical program. AVA6103, a peptide drug conjugate. Read More
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More
(Alliance News) - Avacta Group PLC on Tuesday saw its shares rise, as it said new data demonstrates a favourable delivery profile and advantages of its preCision platform when compared to a marketed antibody drug conjugate. Read More
(Alliance News) - Avacta Group PLC on Monday said it has promoted Francis Wilson to chief scientific officer. Read More
(Correcting that Avacta Group is headquartered in London). Read More
(Alliance News) - Avacta Group PLC on Tuesday saw its shares climb higher as it reported two clinical updates to its faridoxorubicin, or AVA6000, clinical programme. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Wednesday said new data demonstrated that its drug caused "robust and meaningful" tumour shrinkage in patients with salivary gland cancer. Read More
Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company - Expects to announce initial faridoxorubicin phase 1b data in the salivary gland cancer indication next week Wednesday. Back in October, Avacta had said faridoxorubicin showed positive tolerability and safety in patents across both the every three weeks and every two weeks dosing regiments. Faridoxorubicin is a form of doxorubicin designed to reduce the systemic side effects of conventional chemotherapy and concentrate the active payload in the tumour microenvironment. Doxorubicin is a chemotherapy drug used to treat cancer. Read More
(Alliance News) - Avacta Group PLC on Monday said its lead programme faridoxorubicin showed favourable safety and tolerability in patients with salivary gland cancers. Read More